Skip to main content
Ikonisys S.A. logo

Ikonisys S.A. — Investor Relations & Filings

Ticker · ALIKO ISIN · FR00140048X2 LEI · 9695000B742KPNDQ4D05 PA Manufacturing
Open in API
Filings indexed 195 across all filing types
Latest filing 2022-02-01 Board/Management Inform…
Country FR France
Listing PA ALIKO

About Ikonisys S.A.

https://www.ikonisys.com

Ikonisys S.A. is a cell-based diagnostics company specializing in Fluorescence in Situ Hybridization (FISH) technology for genetic analysis. The company develops, manufactures, and markets integrated solutions that include proprietary automated microscopy instruments, advanced software, and reagents. These systems are designed to improve efficiency, accuracy, and standardization for pathologists and laboratory technicians. Ikonisys's technology enables the precise detection and analysis of chromosomal alterations, supporting early and accurate cancer diagnosis, prognosis, and the selection and monitoring of personalized therapies. The platform's automation and digitization features streamline the entire workflow from image acquisition to quantitative interpretation for oncology and genetic testing applications.

Recent filings

Filing Released Lang Actions
Informations privilégiées / Autres communiqués
Board/Management Information Classification · 99% confidence The document is a press release titled "IKONISYS SA ANNONCE LA NOMINATION DE GABRIEL PLAN EN TANT QUE DIRECTEUR DES VENTES FRANCE" (IKONISYS SA ANNOUNCES THE APPOINTMENT OF GABRIEL PLAN AS SALES DIRECTOR FRANCE). The content explicitly details the hiring of a new senior executive (Sales Director) and includes quotes from the Chief Commercial Officer and the new appointee. This directly aligns with the definition of Board/Management Information (MANG), which covers announcements of changes in senior management.
2022-02-01 French
Inside Information / Other news releases
Board/Management Information Classification · 98% confidence The document is a press release announcing a specific personnel change: the appointment of Gabriel Plan as France Sales Director. This type of announcement, detailing changes in senior management or the board of directors, directly corresponds to the definition of 'Board/Management Information' (MANG). It is not an earnings release (ER), a full annual report (10-K), or a general regulatory filing (RNS), as it concerns a specific internal management event.
2022-02-01 English
Inside Information / Other news releases
Investor Presentation Classification · 90% confidence The document is a press release announcing that Sphene Capital has initiated research coverage on Ikonisys stock, including a target price and a 'buy' recommendation. It explicitly provides a link to access the full 'Initiation Report' document. Since the text itself is an announcement about the availability of a research report, and not the comprehensive financial report (like 10-K or IR) or a general regulatory filing (RNS), it best fits the category for Investor Presentations (IP) or, more specifically, a document related to external analysis/research coverage. Given the options, this announcement is closely related to investor materials. However, the core event is the initiation of *coverage* which results in a research report. If the linked document is an Investor Presentation, IP would be suitable. If it's a general announcement about external research, it often falls under Investor Presentation (IP) or sometimes Regulatory Filings (RNS) if no better fit exists. Since the linked document is an 'Initiation Report' which functions similarly to an Investor Presentation providing analysis and valuation, IP is the most appropriate specific category among the choices, as it relates to materials provided to investors about the company's outlook/valuation. Revisiting the definitions: None perfectly capture 'Initiation of Analyst Coverage Announcement'. However, an 'Investor Presentation' (IP) is a detailed presentation for investors focusing on financials, strategy, and market position. A research initiation report serves this exact purpose. It is not an Earnings Release (ER), Interim Report (IR), or a standard regulatory filing (RNS) unless no other fit is found. Given the context of providing valuation and investment rationale to the market, IP is the strongest fit.
2022-01-26 English
Informations privilégiées / Autres communiqués
Report Publication Announcement Classification · 98% confidence The document is a press release from Ikonisys announcing that Sphene Capital has initiated research coverage on its stock, providing a target price and a 'buy' recommendation. The key phrase is the announcement of a research report ('commissioned research') and a link is provided to access the actual document. This structure—a short announcement directing users to the full report—fits the definition of a Report Publication Announcement (RPA). It is not the full research report itself (which would be IP or potentially LTR if it were a legal document, but here it is investment research), nor is it a standard regulatory filing like 10-K or ER. Given the short length (2554 chars) and the explicit instruction to click a link to access the report, RPA is the most appropriate classification.
2022-01-26 French
Acquisition ou cession des actions de l'émetteur / Information relative au contrat de liquidité
Transaction in Own Shares Classification · 95% confidence The document is titled "Bilan semestriel du contrat de liquidité de Ikonisys au 31/12/2021" (Semi-annual balance sheet of the Ikonisys liquidity contract as of 12/31/2021). It details the status and transactions (purchases and sales) related to a liquidity contract (market making agreement) over the second half of 2021. This type of disclosure, reporting on share transactions conducted under a liquidity contract, is typically required periodically (often semi-annually or quarterly) by financial regulations, but it does not fit neatly into the primary financial reporting categories (10-K, IR, ER, MRQ). It is a specific regulatory disclosure concerning share activity. Since it is a detailed report on specific transactions and not just a general announcement of a report's publication, it is best classified as a specific regulatory filing that doesn't match other codes. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for specific, non-standard regulatory disclosures, although it relates closely to share activity (POS). However, POS is for the company buying back its own shares, whereas this is about a third-party liquidity provider's activity on behalf of the company, making RNS the safer general regulatory category.
2022-01-21 French
Acquisition or disposal of the issuer's own shares / Information relating to the liquidity contract
Regulatory Filings Classification · 85% confidence The document is titled "Half year report of IKONISYS's liquidity contract on 31/12/2021" and provides detailed transactional data (buy/sell volume, price, amount) related to a liquidity contract over the second half of 2021. This is a specific periodic report detailing financial/market activity, but it is not a full Annual Report (10-K), a general Earnings Release (ER), or a comprehensive Interim/Quarterly Report (IR) covering all operational results. It is a specialized report concerning market operations (liquidity provision). Since there is no specific category for 'Liquidity Contract Report', I must evaluate the closest fit. It details financial/market activity for a specific period (half-year). It is more detailed than a simple announcement (RPA/RNS) but less comprehensive than a full IR. Given the focus on market operations and periodic reporting, it most closely aligns with specialized financial reporting. However, none of the definitions perfectly capture a 'Liquidity Contract Report'. The closest general category for periodic financial/market disclosures that aren't the main quarterly/annual reports is often 'Regulatory Filings' (RNS) if it's a mandatory disclosure, or potentially a specialized 'Financial Supplement Data' (XLSX) if it were structured data, but here it's narrative/table format. Since it is a formal report detailing activity for a defined period (half-year), and it is not a standard 10-K, AR, or IR, it falls into the category of specialized regulatory disclosure. Given the options, 'RNS' (Regulatory Filings) is the most appropriate fallback for a specific, non-standard periodic disclosure document that doesn't fit the core financial statements or management discussion categories.
2022-01-21 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.